文献速递甲状腺疾病

老年甲状腺功能异常的诊断与管理考量

Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults.
PubMed 文献 · Thyroid · 2025-05-16

本文为叙述性综述,检索2000年1月至2024年12月PubMed与Ovid MEDLINE文献,聚焦老年甲减与甲亢诊治的特殊考量。结论认为应对老年甲状腺功能异常采取个体化诊治,综合考虑年龄相关甲状腺功能生理变化、合并症及多重用药,维持甲状腺功能正常以避免不良事件。

要点

  • 老年临床甲减和甲亢均应治疗,因未治疗心血管风险显著。
  • 老年亚临床甲减TSH<7 mIU/L不推荐左甲状腺素治疗。
  • 老年亚临床甲亢TSH<0.1 mIU/L应治疗,与心血管风险及骨密度丢失相关。

核心结论

  • 老年甲状腺功能异常应采取个体化诊治,综合考虑年龄相关甲状腺功能生理变化、合并症及多重用药,维持甲状腺功能正常以避免不良事件。

研究设计与样本

  • 叙述性综述,检索PubMed与Ovid MEDLINE数据库2000年1月至2024年12月发表的英文相关文献。

主要发现

  • 观察性研究不支持对TSH<7 mIU/L的老年亚临床甲减患者使用左甲状腺素治疗。
  • 观察性数据显示TSH 7.0-9.9 mIU/L的老年亚临床甲减患者心血管死亡和卒中风险增加,TSH≥10 mIU/L者冠心病、心血管死亡和心力衰竭风险增加,提示应考虑左甲状腺素治疗。
  • 临床试验未能显示左甲状腺素较安慰剂改善老年亚临床甲减患者的甲减症状或疲劳。
  • 甲状腺激素替代过度与不足均常见且应避免,基于人群研究显示与不良心血管和骨骼事件相关。
  • 观察性数据显示TSH<0.1 mIU/L的老年亚临床甲亢与心血管风险增加和骨密度丢失相关,应予以治疗。

关键数值与推荐

  • 老年临床甲减和甲亢因未治疗心血管风险显著均应治疗。
  • 老年亚临床甲减TSH<7 mIU/L不推荐左甲状腺素治疗;TSH 7.0-9.9 mIU/L应考虑左甲状腺素治疗;TSH≥10 mIU/L应考虑左甲状腺素治疗。
  • 老年亚临床甲亢TSH<0.1 mIU/L应治疗。
  • 长期低剂量甲巯咪唑可作为老年甲亢患者放射性碘的可行替代方案。

临床怎么用

  • 老年甲状腺功能异常诊治应采取个体化方法,综合考虑年龄相关甲状腺功能生理变化、合并症和多重用药。
  • 应注意维持甲状腺功能正常以避免不良事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid dysfunction is common in older adults and poses diagnostic and management challenges for clinicians. In this narrative review, we present published data focusing on special considerations in the diagnosis and management of hypothyroidism and hyperthyroidism in older adults. Methods: A comprehensive literature search of the PubMed and Ovid MEDLINE databases was conducted from January 2000 to December 2024 to identify pertinent articles in English for this narrative review. Results: Due to significant cardiovascular risk if untreated, both overt hypothyroidism and hyperthyroidism should be treated in older adults. Findings from observational studies do not support treating older adults with subclinical hypothyroidism with a thyrotropin (TSH) <7 mIU/L. However, observational data have demonstrated an increased risk of cardiovascular mortality and stroke in older adults with subclinical hypothyroidism with TSH 7.0-9.9 mIU/L and of coronary heart disease, cardiovascular mortality, and heart failure in those with TSH ≥10 mIU/L, suggesting levothyroxine treatment in these individuals should be considered. Data from clinical trials failed to show improvement with levothyroxine in hypothyroidism symptoms or fatigue in older adults with subclinical hypothyroidism compared with placebo. Over- and under-replacement with thyroid hormone is common and should be avoided, as population-based studies have shown associations with adverse cardiovascular and skeletal events. Subclinical hyperthyroidism with a TSH <0.1 mIU/L should be treated in older individuals as it has been associated with increased cardiovascular risk and bone density loss based on observational data. Randomized controlled trials have shown that long-term low-dose methimazole is a viable alternative to radioactive iodine in older adults with hyperthyroidism. Conclusions: A personalized approach should be undertaken in the diagnosis and management of thyroid dysfunction in older adults. Multiple factors should be considered, including physiological age-related changes in thyroid function, comorbidities, and polypharmacy. Care should be taken to maintain euthyroidism in order to avoid adverse events.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jasim S, Papaleontiou M. Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults. Thyroid. 2025. PMID: 40376729. doi:10.1089/thy.2025.0128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。